Guided by innovation and internationalization, Fosun Pharma increases its investment in R&D and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its R&D and clinical trial capacities for new drugs, and speeds up the R&D and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent R&D, co-development, in-licensing, and in-depth incubation.
We have established efficient international R&D teams in China, the United States, India and other countries
Self-developed small molecule innovator drug
Self-developed innovative biologics
In-licensing innovator drugs
Self-developed biosimilars
Oncology
Non-oncology
| Product | Target | Indication | Pre- clinical | IND | Phase I | Phase II | Phase III | NDA | Approved for Marketing | Development Progress in Other Areas |
| FS-1502 | HER2 | Breast cancer | ||||||||
| Gastric cancer/ Gastroesophageal junction adenocarcinoma | ||||||||||
| FS-1502+HLX10 | HER2/PD-1 | Advanced gastric cancer with HER2+ | ||||||||
| HLX208 | BRAF V600E | Solid Tumor | ||||||||
| HLX208+HLX10 | BRAF V600E/PD-1 | Solid Tumor | ||||||||
| HLX22+HLX02 | HER2/HER2 | Gastric cancer | ||||||||
| SurVaxM | SURVIVIN | Newly diagnosed glioblastoma | ||||||||
| Comirnaty (COVID-19 Vaccine, mRNA) | Spike protein (S protein) | COVID-19 | Hong Kong, China: Adult type approved for marketing Macau, China: Adult type approved for marketing | |||||||
| Avatrombopag Maleate Tablets Doptelet® | TPO receptor agonist | Chronic immune thrombocytopenia | ||||||||
| RT002 | / | Moderate to severe glabellar lines in adults | ||||||||
| Isolated cervical dystonia | ||||||||||
| PA-824 (Pretomanid Tablets) | / | Tuberculosis (MDR-TB) | Approved for marketing in Hong Kong of China | |||||||
| Tenapanor | NHE3 | End-stage renal disease with hyperphosphatemia | ||||||||
| Constipation-predominant irritable bowel syndrome | Approved for marketing in Hong Kong of China | |||||||||
| Fortacin | / | Premature ejaculation | ||||||||
| Opicapone | COMT inhibitor | Parkinsonian syndrome | ||||||||
| OP0595 (Nacubactam) + Cefepime or Aztreonam | Beta-lactamase inhibitor | Infection due to aerobic Gram-negative bacteria with limited treatment options in adults | Phase III MRCT | |||||||
| Grafalon Fu Ke Shu® | / | Prophylaxis of graft versus host disease (GvHD), after hematopoietic stem cell transplantation |
© Novelstar Pharmaceuticals Inc. All rights reserved. | Sitemap